Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures
Phase of Trial: Phase IV
Latest Information Update: 21 Nov 2018
At a glance
- Drugs Perampanel (Primary)
- Indications Partial epilepsies; Tonic-clonic epilepsy
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 21 Nov 2018 According to an Eisai Inc media release, data will be presented at the upcoming American Epilepsy Society Annual Meeting taking place from November 30 to December 4, 2018 in New Orleans.
- 06 Sep 2018 Planned End Date changed from 1 Oct 2019 to 3 Jun 2020.
- 06 Sep 2018 Planned primary completion date changed from 1 Sep 2019 to 3 Jun 2020.